ZIOPHARM Presents Positive Palifosfamide Sarcoma Randomized Phase II Interim Data At Annual Meeting Of The Connective Tissue Oncology Society

 
 


ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) presented today at the 15th Annual Connective Tissue Oncology Society (CTOS) Meeting, positive interim data from the multicenter randomized Phase II trial of palifosfamide (ZymafosTM, ZIO-201) treating patients with unresectable or metastatic soft tissue sarcoma.


Go to Source

People who read this also read

Write a Comment

Gravatars are small images that can show your personality. You can get your gravatar for free today!

Copyright © 2010 Procto Med. All rights reserved.